Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food Effect on Obicetrapib/Ezetimibe FDC Bioavailability
NCT06050291Phase 1Completed
- Sponsor
- NewAmsterdam Pharma
- Start
- Jan 2024
- Primary completion
- Apr 2024
- Modality
- Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of obicetrapib in dyslipidemia and hypercholesterolemia (2 arms), sponsored by NewAmsterdam Pharma. Primary endpoints: Maximum Plasma Concentration at 528 hours, Area Under the Concentration-Time Curve from time 0 to last measurable concentration at 528 hours and 1 more. Started Jan 2024; status: completed.
02
Drugs
obicetrapib
03
Conditions
dyslipidemiahypercholesterolemia
Beyond the preview
Go deeper on NCT06050291.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06050291.